Sales of J&J, Legend cell therapy plateau amid production challenges

Sales of J&J, Legend cell therapy plateau amid production challenges

Source: 
BioPharma Dive
snippet: 

Carvykti, approved in the U.S. for multiple myeloma, generated $55 million in fourth quarter sales, the same as it earned between July and September.